SNGX News and Press, Soligenix Inc. From 08/11/23

ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is avai...

HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment PR Newswire Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Aug. 10, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX...

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis PR Newswire Clear biological signal demonstrated; additional patients to be enrolled PRINCETON, N.J. , July 11, 2023 /PRNewswire/ -- Soligenix, ...

Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily NEW YORK, June 29, 2023 - (ACN Newswire) - Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet me...

ORLANDO, FL / ACCESSWIRE / June 2, 2023 / RedChip Companies will air new interviews with Soligenix, Inc. (Nasdaq:SNGX) and Graphex Group Limited (NYSE American:GRFX) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available i...

2023-05-16 09:11:17 ET Soligenix ( NASDAQ: SNGX ) had received a patent from the European Patent Office titled "Novel Peptides and Analogs for Treatment of Oral Mucositis." ( SNGX ) is trading ~3% higher premarket. This patent complements existing intellectual prop...

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis PR Newswire Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims PRINCETON, N.J. , May 16, 2023 /PRNewswire/ -- Soligenix, Inc...

2023-05-15 09:54:23 ET Soligenix press release ( NASDAQ: SNGX ): Q1 GAAP EPS of -$0.36. Revenue of $0.3M (+50.0% Y/Y). As of March 31, 2023, the company's cash position was approximately $10.3 million. For further details see: Soligenix GAAP EPS of -$0.36, re...

Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results PR Newswire PRINCETON, N.J. , May 15, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing ...

2023-05-11 09:24:33 ET Soligenix ( NASDAQ: SNGX ) said the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to discuss the design of a second phase 3 trial of photodynamic therapy HyBryte ointment to treat cutaneous T-cell lymphoma (CTCL) The company e...